@article{e3254e4bff584d8bae5a9163d3d41ca4,
title = "Sympathetic Ophthalmia: Incidence of Ocular Complications and Vision Loss in the Sympathizing Eye",
abstract = "Purpose: To report the frequency on presentation and subsequent incidence of ocular complications and vision loss in patients with sympathetic ophthalmia (SO) and to describe factors associated with decreased vision in the sympathizing eye. Design: Multicenter retrospective case series. Methods: setting: Three academic tertiary care uveitis clinics. study population: Eighty-five patients with SO from 1976 to 2006. observation procedures: Review of existing medical records. main outcome measures: Incident visual acuity (VA) loss to 20/50 or worse and 20/200 or worse and the median acuity over time. Results: Twenty-six percent of patients with SO presented with a VA of 20/200 or worse in their sympathizing eye. Further development of vision loss to 20/200 or worse occurred at the rate of 10% per person-year (PY). Ocular complications were seen in the sympathizing eye in 47% of patients at presentation; further development of new complications occurred at the rate of 40%/PY. The ocular complications most often associated with decreased vision were cataract and optic nerve abnormality. Exudative retinal detachment and active intraocular inflammation were significantly associated with poorer VA in the sympathizing eye. The benefits of corticosteroids were indirectly demonstrated as their use led to more rapid disease inactivation. Fifty-nine percent of patients maintained a VA of better than 20/50 in their sympathizing eye; and 75% maintained a VA of better than 20/200. Conclusions: Although ocular complications were seen in many sympathizing eyes with SO, most patients maintained functional VA. The presence of an exudative retinal detachment and active intraocular inflammation correlated with poorer vision in the sympathizing eye.",
author = "Anat Galor and Davis, {Janet L.} and Flynn, {Harry W.} and Feuer, {William J.} and Dubovy, {Sander R.} and Vikram Setlur and Kesen, {Muge R.} and Goldstein, {Debra A.} and Tessler, {Howard H.} and Ganelis, {Irina Bykhovskaya} and Jabs, {Douglas A.} and Thorne, {Jennifer E.}",
note = "Funding Information: This study was supported by Grant Nos. EY-13707 (Dr Thorne) and EY-00405 (Dr Jabs); Core Center Grant No. P30 EY014801 (Bascom Palmer Eye Institute, Miami, Florida); the National Eye Institute, Bethesda, Maryland; and unrestricted funds from Research to Prevent Blindness, New York, New York. Dr Thorne is the recipient of a Research to Prevent Blindness Harrington Special Scholars Award. Dr Davis received grant support from Novartis and the Jaime Marti Foundation (>$10,000). Dr Flynn received consulting fees from Alcon, Allergan, Genentech, Lilly, and Pfizer (≤$10,000) and has stock in Optimedica (≤$10,000). Dr Feuer received grant support from National Institutes of Health (NIH) (>$10,000) and Abbott and New World Medical (≤$10,000). Dr Goldstein received consulting fees from Allergan, Genzyme, and Novartis (≤$10,000); has stock in Amgen, Johnson & Johnson, and Merck (>$10,000); and received additional grant support from NIH (>$10,000). Dr Jabs received grant support from NIH and Abbott (≤$10,000). Dr Thorne received grant support from NIH and Research to Prevent Blindness Inc (>$10,000). Involved in conception and design of study (J.L.D., H.W.F., D.A.J., J.E.T.); analysis and interpretation of data (A.G., J.D., H.W.F., D.A.G., H.T., D.A.J., J.E.T.); writing the article (A.G., W.F.); critical revision of the manuscript (A.G., J.L.D., H.W.F., S.R.D., W.F., V.S., M.K., D.A.G., H.H.T., I.B.G., D.A.J., J.E.T.); final approval of the manuscript (A.G., J.L.D., H.W.F., S.R.D., W.F., V.S., M.K., D.A.G., H.H.T., I.B.G., D.A.J., J.E.T.); data collection (A.G., V.S., M.K., I.B.G.); statistical expertise (A.G., W.F., J.E.T., D.A.J.); and literature search (A.G.). The Johns Hopkins University, University of Miami, and University of Illinois at Chicago Institutional Review Boards reviewed and approved this study, which was conducted in accordance with the principles of the Declaration of Helsinki. ",
year = "2009",
month = nov,
doi = "10.1016/j.ajo.2009.05.033",
language = "English (US)",
volume = "148",
pages = "704--710.e2",
journal = "American journal of ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "5",
}